Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London. Every ticket, every bid, every moment helps us move closer to a cure.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Join the type 1 diabetes community and come together, raising awareness and vital funds for T1D.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > NICE Approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales
NHS England and Wales are set to roll out implementation over the next five years. The treatment will start to be prescribed early in the New Year.
Hybrid closed loop (HCL), also known as the ‘artificial pancreas’ or automated insulin delivery system, is a treatment at the frontier of health technology, which takes a continuous glucose monitor (CGM) and introduces an advanced algorithm to automate the delivery of insulin through a pump.
Not only does HCL make day-to-day life easier, it also enables people with type 1 diabetes to live healthier lives without fear, by reducing the risks of complications including heart failure, loss of limbs, kidney failure and sight loss.
Hilary Nathan, Policy Director at JDRF said: “Hybrid closed loop technology breaks new ground in medical research and health technology. It’s a beautiful set of algorithms, which will save lives and heartbreak, as well as in the long-term save the NHS the cost of cardiovascular and retinal surgery, kidney dialysis and transplantation.
“It helps lift the burden of living with type 1 diabetes, reducing the risk of potentially fatal high and low glucose levels and reduces the likelihood of long-term complications. In type 1 medical research we stand on the shoulders of the Nobel Prize winning giants, Professors Banting and Macleod for their discovery of insulin. Hybrid closed loop defines a new era for medicine”
Professor Partha Kar, national specialty adviser for diabetes at NHS England, said: “This will transform the lives of the majority of people living with type 1 diabetes in England and Wales. Around 150,000 people living with type 1 diabetes in England alone will have access to HCL over the next five years.
“This tech might sound sci-fi like, but it will have a dramatic impact on the quality of people’s lives, not to mention outcomes – it is as close to the holy grail of fully automated insulin as science can provide at the moment, where people with type 1 diabetes can get on with their lives without worrying about glucose levels or medication.”
The development of HCL has been driven by JDRF. Over the past 16 years, we have funded over £115 million in international research and clinical trials. JDRF’s advocacy has been instrumental in making this technology available on the NHS in Scotland, Wales and England.
The roll out will be phased over five years, with all children and young people, women who are pregnant or planning a pregnancy, and those people who already have an insulin pump to be offered HCL. The technology will also be offered to adults with an average HbA1c reading of 7.5% or more. NICE guidelines recommend people should aim for an HbA1c level of 6.5% or lower. Adults who experience disabling hypoglycaemia will also be offered the technology.
More work needs to be done in gaining access in Northern Ireland to this treatment. However, today’s news will create the momentum and evidence to help secure parity across the four nations.
You can see the full guidance on the NICE website.
Nina Willer tells us about using hybrid closed loop technology during pregnancy.
Find out how we've funded hybrid closed loop research for the past 20 years.
We’re aware of growing concern around insulin supply in the UK, and we want to reassure our community that this is not a general insulin shortage. There is no need to change the type of insulin you use.
If you use the Dexcom G6 app on your Android smartphone, the newest Android 16 operating system may disrupt how the app functions.
We're calling for urgent reform as new report reveals older people with T1D are systematically failed by health and social care services.
Breakthrough T1D has helped organise an event hosted by Tomislav Sokol titled ‘Accelerating Breakthroughs to Address Unmet Needs in Type 1 Diabetes.’
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.
